| Marston Optometry | |
|
32037 Plymouth Rd, Livonia, MI 48150-1908 | |
| (734) 421-5454 | |
| (734) 421-6133 |
| Full Name | Marston Optometry |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 32037 Plymouth Rd, Livonia, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306267513 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4901004661 (Michigan) | Primary |
| Provider Name | Carol L Marston Foucher |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1255312195 PECOS PAC ID: 1557322948 Enrollment ID: I20100621000561 |
News Archive
Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
Before the digital age, neuroscientists got their information in the library like the rest of us. But the field's explosion has created nearly 2 million papers - more data than any researcher can read and absorb in a lifetime.
Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.
ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).
Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company's proprietary technology that targets tumor blood vessels (anti angiogenic antigen).
› Verified 3 days ago
| Provider Name | Shea B Ferree Carney |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1326326026 PECOS PAC ID: 7517130040 Enrollment ID: I20111028000531 |
News Archive
Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
Before the digital age, neuroscientists got their information in the library like the rest of us. But the field's explosion has created nearly 2 million papers - more data than any researcher can read and absorb in a lifetime.
Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.
ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).
Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company's proprietary technology that targets tumor blood vessels (anti angiogenic antigen).
› Verified 3 days ago
| Provider Name | Marie P Humphrey |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1740631290 PECOS PAC ID: 4183911423 Enrollment ID: I20160929001758 |
News Archive
Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
Before the digital age, neuroscientists got their information in the library like the rest of us. But the field's explosion has created nearly 2 million papers - more data than any researcher can read and absorb in a lifetime.
Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.
ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).
Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company's proprietary technology that targets tumor blood vessels (anti angiogenic antigen).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marston Optometry 32037 Plymouth Rd, Livonia, MI 48150-1908 Ph: (734) 421-5454 | Marston Optometry 32037 Plymouth Rd, Livonia, MI 48150-1908 Ph: (734) 421-5454 |
News Archive
Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.
Before the digital age, neuroscientists got their information in the library like the rest of us. But the field's explosion has created nearly 2 million papers - more data than any researcher can read and absorb in a lifetime.
Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.
ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).
Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company's proprietary technology that targets tumor blood vessels (anti angiogenic antigen).
› Verified 3 days ago
Omar Mallah, OD Optometrist Medicare: Medicare Enrolled Practice Location: 29474 7 Mile Rd, Livonia, MI 48152 Phone: 248-615-2815 | |
Dr. James S Engstrom, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 13700 Middlebelt Rd, Livonia, MI 48150 Phone: 734-427-2944 | |
Marston Optometry, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 32037 Plymouth Rd, Livonia, MI 48150 Phone: 734-421-5454 Fax: 734-421-6133 | |
Mr. Gerald N Blaize, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 33012 7 Mile Rd, Livonia, MI 48152 Phone: 248-482-2020 Fax: 248-476-6441 | |
Svs Vision 06 Optometrist Medicare: Not Enrolled in Medicare Practice Location: 29691 7 Mile Rd, Livonia, MI 48152 Phone: 734-421-2844 Fax: 734-421-2878 | |
K & K Optical Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 28209 7 Mile Rd, Livonia, MI 48152 Phone: 248-777-2830 Fax: 248-777-9376 | |
Dr. Carol Lynn Marston-foucher, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 32037 Plymouth Rd, Livonia, MI 48150 Phone: 734-421-5454 Fax: 734-421-6133 |